Search results
Results from the WOW.Com Content Network
IMS stood for Intercontinental Medical Statistics. It was the largest vendor of U.S. physician prescribing data. [2] [3] [4] IMS Health was founded in 1954 by Bill Frohlich and David Dubow with Arthur Sackler having a hidden ownership stake. [5] In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green ...
[28] [29] IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles. [ 30 ] [ 31 ] The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS. [ 9 ]
In October 2020, Hims closed a deal with Oaktree Capital Management to go public through a blank check company, reaching a valuation of $1.6 billion. [7] As part of the deal, the company was renamed Hims & Hers Health Inc. [11] The transaction was completed in January 2021, and the company started trading publicly on the New York Stock Exchange.
IMS Health to Issue Full-Year 2012 Financial Results on March 4, Conference Call for Note Holders Scheduled for March 8 DANBURY, Conn.--(BUSINESS WIRE)-- IMS Health plans to post for note holders ...
In August 2000, Richard C. Breon was hired to lead the organization as CEO, and sought to form an integrated health care system. [6] In 2012, Spectrum Health System was recognized as one of the Top 50 Integrated Health Care Networks in the United States by IMS Health. [7] In July 2018, Tina Freese-Decker was named CEO to succeed Richard Breon. [8]
Beyond its large insurance business, UHG also owns, among other things, a pharmacy benefits manager (PBM), surgical clinics, home health providers, and the nation’s largest physician group.
According to IMS Health, the pharmaceutical industry auditing service, Prasco is one of the fastest growing pharmaceutical companies in the industry, in terms of relative growth and prescriptions dispensed for the years 2005 and 2006. [1]
The appeal of analyzing big data for better outcomes isn't limited to doctors and patients. It's also disrupting how pharmaceutical and biotechnology companies develop drugs. As cost-conscious ...